Patient considerations

Before prescribing LATISSE® to your patients with eyelash hypotrichosis, discuss ocular health with those who have or have had a history of the following1:

  • Previously diagnosed with eye pressure problems Patients who have been previously diagnosed with elevated intraocular pressure (IOP) or have a history of elevated IOP should speak to an eye care specialist prior to starting LATISSE® solution.


  • Currently on IOP-lowering medications Patients who are currently using IOP-lowering medications should speak with an eye care specialist prior to starting LATISSE® solution.


  • Have risk factors for or were previously diagnosed with glaucoma Patients with risk factors for glaucoma or a family history of glaucoma should speak to an eye care specialist prior to starting LATISSE®.


  • Currently pregnantThere are no adequate and well-controlled studies of bimatoprost ophthalmic solution 0.03% administration in pregnant women. Because animal reproductive studies are not always predictive of human response, LATISSE® should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus.


  • Nursing mothers It is not known whether LATISSE® solution is excreted in human milk, although in animal studies, bimatoprost has been shown to be excreted in breast milk. Because many drugs are excreted in human milk, caution should be exercised when LATISSE® is administered to a nursing woman.


  • Pediatric use Safety and effectiveness in pediatric patients have not been established.


  • Have risk factors for macular edema LATISSE® solution should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.